The world's first clinically validated
Digital Twin and AI-powered nutrition for
tear production.
Dry eye affects 344 million people worldwide. en-TEAR delivers a greater improvement in tear production than the leading prescription option.
- Food-grade ingredients
- Compliant with FDA / EFSA standards
- Validated by clinical studies
Clinically meaningful improvement in tear production.
In the clinical study, en-TEAR supported a clinically meaningful improvement in ocular surface health, with higher tear production results compared with standard care.
Effectivetear production
en-TEAR 60.7% tear production increase
Leading Rx option (cyclosporine) ≈40%
Measurabletear volume
en-TEAR +6.03 mm Schirmer test
Leading Rx option (cyclosporine) +2-3 mm
Sustainedresults
en-TEAR improvement maintained at 16 weeks
Leading Rx option (cyclosporine) fades after you stop
Pilot study (n=20). The manuscript is currently under journal review, with publication expected in the first half of 2026.
See the clinical study
Dry eye support that starts in the gut.
en-TEAR is a clinically validated nutraceutical formulation that supports ocular surface health by targeting the gut microbiome.
One formulation, three ways to bring it to market.
Ready-to-market
The full 8-week program: 60 daily sachets in retail-ready packs, shipped as finished product. For distributors, pharmacy chains and clinics that want to take en-TEAR straight to their market.
Premix
The same formulation as a bulk powder premix. We supply it to manufacturers and supplement brands that run en-TEAR on their own filling and packaging lines.
Formulation licensing
For food and beverage companies: license the formulation and build it into your own product, whether that's a supplement, a functional food or a drink. We handle the technical transfer with you.
344 million
people worldwide affected by dry eye.
The vast majority of current options for dry eye only manage symptoms.
A significant portion of patients do not achieve adequate relief, even after prolonged use of artificial tears and eye drops.
en-TEAR addresses the root of the problem by targeting the gut-eye axis, supporting ocular surface health from within.
We target the root cause, not the surface.
Root-cause triggers
Tear film instability
Insufficient production or rapid evaporation.
Ocular surface inflammation
Accumulation of pro-inflammatory cytokines on the ocular surface.
Gut dysbiosis
Weakened gut barrier and reduced anti-inflammatory short-chain fatty acids.
The en-TEAR approach
- Microbiome-derived precursors: correcting dysbiosis and increasing beneficial bacterial production.
- Supporting the production of beneficial compounds.
- Suppressing inflammatory signaling pathways.
ENBIOSIS targets the root cause of dry eye, supporting ocular surface health through its en-TEAR formulation.
The ENBIOSIS
formulation engine.
We program the gut microbiome to produce its own therapeutic compounds, transforming the body into a self-sustaining production system.
en-TEAR supports the body's own production mechanisms.
We have developed a Digital Twin & AI powered platform to formulate supplements that program the gut microbiome to produce its own health-promoting compounds, transforming the body into a self-sustaining production system and delivering sustainable solutions at the root cause of each health condition.
Simulation of the gut microbiome
Identifies the therapeutic compounds the body needs.
AI precursor selection
Selects the specific food-grade precursors required to produce those compounds.
How we build formulations?
Prediction
Microbiome data → Digital twin simulation → Metabolic output prediction
Discovery
Target metabolites → Retrosynthesis modelling → Precursor identification
Design
Food-grade substrates → Minimal precursor sets → Targeted formulation design
Validation
Targeted formulation design → Large-scale RCT validation → Clinical evidence
en-TEAR begins with a biological target, not an ingredient.
Conventional supplements rely on antioxidant and anti-inflammatory ingredients. en-TEAR first identifies disrupted metabolic pathways along the gut-eye axis, then determines the supporting ingredients through computational modeling.
The old way
Conventional dry eye supplement
Antioxidant + anti-inflammatory nutritional support
- Vitamin C
- Vitamin E
- Omega-3 fatty acids
- Lutein
- Zeaxanthin
- Zinc
- Curcumin
- Vitamin D
Our formula contains none of these ingredients.
Our approach
en-TEAR
- Every ingredient has a defined biological purpose.
- Uses food-grade ingredients compliant with FDA and EFSA.
- Targets dry eye biology via the gut-eye axis and inflammation.
Contains food-grade prebiotic substrates selected to support short-chain fatty acid production in the gut.
Independently recognized, evidence-based technology.
ENBIOSIS is a platform built over more than 15 years of R&D across thousands of microbiome profiles. It forms the foundation of the proprietary data bank that underpins our models.
Backed by peer-reviewed publications, patent-protected formulations, and the UK Tech Rocketship Gold Award, our scientific foundation has grown into a technology trusted by partners across 16 countries.
Gold Medal winner among 256 high-potential technology ventures from Europe, Turkey, and Israel.
Exclusive territory
Tailored to your market and region.
Clinical support
Study data, endpoints, and the full evidence base.
Marketing support
Brand, education, and go-to-market assets.
Would you like to offer this clinically validated dry eye product to your customers?
Who we partner with.
We work with partners who share our commitment to evidence-based care, from the clinic to the shelf to the region.
Distributors
Bring a category-defining nutraceutical to your market, backed by a globally recognized, award-winning platform.
Eye clinics & optometrists
Give your dry eye patients a clinically validated, root-cause option that complements in-office care.
Pharmacies
Add a differentiated, science-led dry eye product to your shelves, set apart from conventional supplements.
Online retailers
List a category-defining, science-led dry eye product with the content to convert online shoppers.
Health brands
Bring an AI-designed, clinically validated formulation into your supplement, functional food, or beverage line.
Wellness & longevity clinics
Add a microbiome-based formulation to your protocols, aligned with a systems approach to health.
The world's first Digital Twin and AI-powered nutraceutical formulation engine.
Science first, from day one
ENBIOSIS was founded in 2019 on a single conviction: that food-grade inputs can create clinically meaningful effects. Today we are shaping the future of health technology as the world's first Digital Twin and AI-powered nutraceutical formulation engine.
The company's foundations were laid in 2018, when Prof. Dr. Özkan Ufuk Nalbantoğlu and entrepreneur Ömer Özkan crossed paths. Since 2004, Prof. Dr. Nalbantoğlu has developed the microbiome and AI algorithms behind his contribution to the Earth Microbiome Project. Ömer Özkan brings the technology-commercialization experience that turns this scientific foundation into products with global impact.
en-TEAR, the first product of this platform, is a functional supplement that targets dry eye syndrome through the gut-eye axis, with efficacy clinically validated.
Ömer Özkan
Founder & CEO
Prof. Dr. Özkan Ufuk Nalbantoğlu
Founder & CTO
The new era of nutraceuticals
ENBIOSIS Biotechnology designs clinically validated, food-grade nutraceutical formulations powered by Digital Twin and AI technology. Our platform maps the gut microbiome at a biological level, identifying the precise food-grade inputs needed to support specific health conditions through the gut microbiome.
The platform produces personalized formulations across a wide range of health areas, from cognitive function to skin and eye health.
en-TEAR is ENBIOSIS's first clinically validated nutraceutical formulation, developed for dry eye. It targets the gut-eye axis, supporting microbial balance and ocular surface health from within.
Why we built ENBIOSIS
We are building a new paradigm where the gut microbiome becomes a precise, clinically actionable control system for human health. Using Digital Twin and AI technology, we design formulations that enable the body to produce its own therapeutic molecules, transforming nutrition from passive supplementation into a programmable intervention. en-TEAR is where this vision begins, establishing a new category in ocular nutrition built on systems biology and clinical evidence.
What we stand for
Precision over tradition
Every component in an ENBIOSIS formulation is selected because it serves a specific, measurable biological function, not because it is familiar.
Evidence before claim
Clinical validation is a prerequisite at ENBIOSIS, not a final step. Every claim we make is grounded in data, and every formulation is tested before it reaches the market.
Partnership with practitioners
Our formulations reach patients through healthcare professionals. We support that relationship with clear science, transparent communication, and dedicated clinical resources for every practitioner who recommends our products.
We begin with a question
Most nutraceuticals begin with ingredients. We begin with a question: what does the body need to rebalance itself? Our Digital Twin and AI technology maps the answer at a systems level, then builds the formulation to match.
The scientific evolution of ENBIOSIS
Digital Twin modeling
Developing digital twin models of the human gut microbiome to simulate how microbial communities process different inputs and generate metabolic outputs.
Metabolic pathway identification
Identifying target metabolic pathways and key microbial functions associated with specific health outcomes through simulation and scientific validation.
Retrosynthetic formulation design
Using AI-driven retrosynthesis to identify food-grade precursors that can be converted by the microbiome into target metabolites.
Formulation & deployment
Translating these insights into ready-to-use nutraceutical formulations, designed for scalable integration across global markets.
The science behind our nutraceutical formulation
years
of microbiome research
Q1 publications
peer-reviewed validation
countries
where the platform is applied
ENBIOSIS is built on over 15 years of microbiome research, validated through four Q1 publications and applied across 16+ countries. This scientific foundation shapes every formulation we develop, from the biological targets we identify to the clinical evidence we generate.
en-TEAR is the first product of this platform and the first clinically validated nutraceutical formulation designed to support dry eye health through the gut microbiome.
Let's work together.
We are now expanding en-TEAR through regional distribution partners. In a first meeting, let's map your territory and terms, and share the full distributor pack.